register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03063203 | [
{
"id_field": "org_study_id",
"id_value": [
"201911185-1001"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"3P50CA171963-06S1"
]
}
] | https://clinicaltrials.gov/study/NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations. | An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | [
{
"description": "* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least >20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference<br/>* Transplant eligible... | [
{
"design_group_description": "* Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle<br/>* Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. A... | [
"Acute Myeloid Leukemia",
"Acute Myeloid Leukemia, Relapsed, Adult"
] | [
"Washington University School of Medicine"
] | [
"National Cancer Institute",
"Janssen Pharmaceuticals, Inc.",
"National Institutes of Health"
] | [
[
{
"name": "地西他滨",
"lang": "CN"
},
{
"name": "Decitabine",
"lang": "EN"
}
]
] | null |
NCT06498986 | [
{
"id_field": "org_study_id",
"id_value": [
"BL-B01D1-207"
]
}
] | https://clinicaltrials.gov/study/NCT06498986 | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer. | A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | [
{
"description": "Administration by intravenous infusion for a cycle of 3 weeks.",
"name": "BL-B01D1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BMS-986507",
"iza-bren",
"izalontamab brengitecan"
],
"type": "Drug"
},
{
"description": "O... | [
{
"design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or... | [
"Non-small Cell Lung Cancer"
] | [
"Sichuan Baili Pharmaceuticals Co.,Ltd"
] | [
"Baili Bio Chengdu Pharmaceutical Co. Ltd."
] | [
[
{
"name": "伦康依隆妥单抗",
"lang": "CN"
},
{
"name": "Izalontamab Brengitecan",
"lang": "EN"
}
],
[
{
"name": "甲磺酸奥希替尼",
"lang": "CN"
},
{
"name": "Osimertinib mesylate",
"lang": "EN"
},
{
"name": "オシメルチニブメシル酸塩",
"lang":... | null |
NCT02857582 | [
{
"id_field": "org_study_id",
"id_value": [
"ACHIM 1"
]
}
] | https://clinicaltrials.gov/study/NCT02857582 | Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile | Patients who have received antibiotics and thereafter developed diarrhea are investigated for presence of Clostridium difficile toxin. Primary treatment is given with oral metronidazole/vancomycin. In case of relapse, secondary treatment is given with either cultured gut microbiota rectally or oral vancomycin in sequen... | Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile | [
{
"description": "Secondary treatment for C diff in replacement for regular vancomycin.",
"name": "Cultured human intestinal microbiota",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Anaerobic cultured human intestinal microbiota (ACHIM)"
],
"type": "Biologic... | [
{
"design_group_description": "Secondary treatment for relapse of Clostridium difficile infection.",
"design_group_title": "Vancomycin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"interventio... | [
"Clostridium Difficile"
] | [
"University of Uppsala"
] | [
"Karolinska Institutet"
] | [
[
{
"name": "甲硝唑",
"lang": "CN"
},
{
"name": "Metronidazole",
"lang": "EN"
},
{
"name": "メトロニダゾール",
"lang": "JP"
}
]
] | null |
NCT05548296 | [
{
"id_field": "org_study_id",
"id_value": [
"ACR-368-201 (GOG 3082)"
]
}
] | https://clinicaltrials.gov/study/NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer. | A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer | [
{
"description": "ACR-368 is an experimental drug",
"name": "ACR-368",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"prexasertib"
],
"type": "Drug"
},
{
"description": "Sensitization of tumor cells is provided through administration of ULDG",
"name... | [
{
"design_group_description": "ARM 1: Participants with OncoSignature Positive Tumors will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy.",
"design_group_title": "OncoSignature Positive Tumors",
"design_group_type": "Experimental",
"design_group_type_nor... | [
"Endometrial Adenocarcinoma"
] | [
"Acrivon AB"
] | [
"The Gynecologic Oncology Group"
] | [
[
{
"name": "普瑞色替",
"lang": "CN"
},
{
"name": "Prexasertib Mesylate Hydrate",
"lang": "EN"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lan... | [
{
"identifier_source": [
{
"code": "dad53aea32528a3aade9d52a448e225d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ACR-368-201"
},
{
"identifier_source": [
{
"code": "3d52eea950204aa08d88eaa8ea2a0a2e",
"source": "CT_RESU... |
NCT05748834 | [
{
"id_field": "org_study_id",
"id_value": [
"BRE 381"
]
},
{
"id_field": "secondary_id",
"id_value": [
"BRE 381"
]
}
] | https://clinicaltrials.gov/study/NCT05748834 | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to:<br/>* Learn how well the combination of tucatinib and Doxil works<br/>* Learn more about the side... | Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer | [
{
"description": "Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.",
"name": "Tucatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tukysa"
],
"type": "Drug"
},
{
"description": "Particip... | [
{
"design_group_description": "Participants will receive tucatinib 300mg by mouth twice daily continuously in combination with Doxil 40mg/m2 given intravenously on day 1 of each cycle. Cycles will be 28 days. Up to 36 participants will be enrolled in this Phase 2 study.",
"design_group_title": "Tucatinib Ex... | [
"Breast Cancer"
] | [
"Scri Development Innovations LLC"
] | [
"Pfizer Inc.",
"Seagen, Inc."
] | [
[
{
"name": "盐酸多柔比星脂质体",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride liposomal",
"lang": "EN"
}
],
[
{
"name": "妥卡替尼",
"lang": "CN"
},
{
"name": "Tucatinib",
"lang": "EN"
},
{
"name": "ツカチニブ エタノール付加物",
"lang... | null |
NCT06797635 | [
{
"id_field": "org_study_id",
"id_value": [
"1022-010"
]
},
{
"id_domain": "MSD",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MK-1022-010"
]
},
{
"id_domain": "EU CT",
"id_field": "secondary_id",
"id_type": "Registry Ident... | https://clinicaltrials.gov/study/NCT06797635 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:<br/>* About the safety of the study treatments and if people tolerate them<br/>* If... | An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early... | [
{
"description": "Administered via IV infusion as neoadjuvant treatment",
"name": "Patritumab deruxtecan",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"HER3-DXd",
"MK-1022",
"U3-1402"
],
"type": "Biological"
},
{
"description": "Administer... | [
{
"design_group_description": "In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week... | [
"Breast Neoplasms",
"Breast Cancer"
] | [
"Merck Sharp & Dohme LLC"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "德帕瑞妥单抗",
"lang": "CN"
},
{
"name": "Patritumab Deruxtecan",
"lang": "EN"
}
],
[
{
"name": "奥拉帕利",
"lang": "CN"
},
{
"name": "Olaparib",
"lang": "EN"
},
{
"name": "オラパリブ",
"lang": "JP"
}
],
[
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MK-1022-010"
},
{
"identifier_source": [
{
"code": "a25a5a2ed584a2e0a9a49d289e2a5525",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
... |
NCT05104567 | [
{
"id_field": "org_study_id",
"id_value": [
"ACT16902"
]
},
{
"id_domain": "ICTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"U1111-1251-4981"
]
},
{
"id_domain": "Merck Sharp & Dohme LLC.",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT05104567 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer. This study is structured as ... | A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer | [
{
"description": "Solution for infusion: intravenous infusion",
"name": "THOR-707",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pegenzileukin"
],
"type": "Drug"
},
{
"description": "Solution for infusion: intravenous infusion",
"name": "Pembroliz... | [
{
"design_group_description": "Participants with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC), regardless of programmed cell death-ligand 1 (PD-L1) expression (any combined positive score [CPS]), who had received at least 1 but no more than 2 prior lines of treatment and had pro... | [
"Oesophageal Squamous Cell Carcinoma",
"Gastric Cancer",
"Hepatocellular Carcinoma",
"Colorectal Cancer",
"Oesophageal Adenocarcinoma"
] | [
"Sanofi"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "Pegenzileukin",
"lang": "EN"
}
],
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
... | null |
NCT05450965 | [
{
"id_field": "org_study_id",
"id_value": [
"2412GCCC ; HP-00109457"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01CA273216-01"
]
}
] | https://clinicaltrials.gov/study/NCT05450965 | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cel... | A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | [
{
"description": "Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.",
"name": "Onvansertib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Onvansertib",
"design_group_title": "Single Treatment Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Onvansertib at a dose of 15 mg/m2 ... | [
"Small-cell Lung Cancer",
"Small Cell Lung Carcinoma"
] | [
"University of Maryland Baltimore"
] | [
"National Cancer Institute",
"Cardiff Oncology, Inc."
] | [
[
{
"name": "Onvansertib",
"lang": "EN"
}
]
] | null |
NCT03841747 | [
{
"id_field": "org_study_id",
"id_value": [
"012342QM"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-000188-10"
]
},
{
"id_field": "acronym",
"id_value": [
"PELICAN"
]
}
] | https://clinicaltrials.gov/study/NCT03841747 | Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer | PELICAN is a randomised phase II trial that aims to evaluate the efficacy and safety of paclitaxel plus pembrolizumab relative to paclitaxel alone, in patients with locally advanced or metastatic ER-positive, HER2-negative, Luminal B breast cancer who have received no prior chemotherapy for advanced or metastatic disea... | A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Paclitaxel Weekly in ER-positive, Luminal B Metastatic Breast Cancer | [
{
"description": "200 mg Pembrolizumab IV Q3W.",
"name": "Pembrolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"KEYTRUDA",
"lambrolizumab"
],
"type": "Drug"
},
{
"description": "80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cy... | [
{
"design_group_description": "200 mg Pembrolizumab IV Q3W plus 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.",
"design_group_title": "Pembrolizumab + Paclitaxel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"inte... | [
"Breast Cancer"
] | [
"Queen Mary University of London"
] | [
"Merck Sharp & Dohme Corp.",
"Istituto Europeo di Oncologia Srl"
] | [
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PELICAN"
}
] |
NCT05014646 | [
{
"id_field": "org_study_id",
"id_value": [
"21049"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2021-07263"
]
},
{
"id_domain": "City of Hope Medical Center",
... | https://clinicaltrials.gov/study/NCT05014646 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent. | Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple Myeloma | [
{
"description": "Given PO",
"name": "Cholestyramine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cholybar",
"Colestyramine",
"Duolite AP143 Resin",
"Questran",
"Questran Light"
],
"type": "Drug"
},
{
"description": "Given PO... | [
{
"design_group_description": "Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (leflunomide)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b... | [
"Smoldering Plasma Cell Myeloma"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "考来烯胺",
"lang": "CN"
},
{
"name": "Cholestyramine",
"lang": "EN"
},
{
"name": "コレスチラミン",
"lang": "JP"
}
],
[
{
"name": "来氟米特",
"lang": "CN"
},
{
"name": "Leflunomide",
"lang": "EN"
},
{
"nam... | null |
NCT05589610 | [
{
"id_field": "org_study_id",
"id_value": [
"EQ101-104-01"
]
}
] | https://clinicaltrials.gov/study/NCT05589610 | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 week... | An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | [
{
"description": "EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses",
"name": "EQ101",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "EQ101 weekly",
"design_group_title": "EQ101",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "EQ101, 2 mg/kg, once weekly dosing, for a total ... | [
"Alopecia Areata",
"Alopecia",
"Alopecia Totalis",
"Alopecia Universalis"
] | [
"Equillium, Inc."
] | [
"Equillium AUS Pty Ltd."
] | [
[
{
"name": "BNZ-1",
"lang": "EN"
}
]
] | null |
NCT00000819 | [
{
"id_field": "org_study_id",
"id_value": [
"ACTG 271"
]
},
{
"id_domain": "DAIDS ES Registry Number",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"11247"
]
},
{
"id_field": "secondary_id",
"id_value": [
"11247;ACTG 27... | https://clinicaltrials.gov/study/NCT00000819 | A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN) | To determine the efficacy and safety of prednisone in patients with HIV-associated nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and creatinine clearance.<br/>HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal insufficiency, and distin... | A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN) | [
{
"name": "Prednisone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"HIV Infections",
"AIDS-Associated Nephropathy"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"The Upjohn Co."
] | [
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
]
] | null |
NCT02383251 | [
{
"id_field": "org_study_id",
"id_value": [
"GINECO-OV231"
]
},
{
"id_field": "acronym",
"id_value": [
"TAPAZ"
]
}
] | https://clinicaltrials.gov/study/NCT02383251 | Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer | Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance. | A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance | [
{
"description": "Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg",
"name": "Pazopanib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Votrient"
],
"type": "Drug"
},
{
"description": "A... | [
{
"design_group_description": "Arm 1 :<br/>Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.<br/>Then:<br/>* Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or ... | [
"Ovarian Cancer"
] | [
"Arcagy-Gineco"
] | [
"Novartis AG"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "培唑帕尼",
"lang": "CN"
},
{
"name": "Pazopanib Hydrochloride",
"lan... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "959aa5ae9e80a24a955ad2298a2a9922",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TAPAZ"
}
] |
NCT01137916 | [
{
"id_field": "org_study_id",
"id_value": [
"CSTI571BDE70"
]
}
] | https://clinicaltrials.gov/study/NCT01137916 | Study to Evaluate Imatinib in Desmoid Tumors | The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy. | Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss | [
{
"description": "800 mg",
"name": "Imatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Glivec"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Imatinib 800 mg",
"design_group_title": "drug",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "800 mg",
"intervention_name": "Imatini... | [
"Aggressive Fibromatosis",
"Desmoid Tumor"
] | [
"Heidelberg University (EMCL)"
] | [
"Novartis AG"
] | [
[
{
"name": "甲磺酸伊马替尼",
"lang": "CN"
},
{
"name": "Imatinib mesylate",
"lang": "EN"
},
{
"name": "イマチニブメシル酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "ead542d33d22a25e29e2930a9ed5a005",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "GISG-01"
}
] |
NCT00729222 | [
{
"id_field": "org_study_id",
"id_value": [
"7418-503"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MK7418-503"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2008_532"
]
}
] | https://clinicaltrials.gov/study/NCT00729222 | Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503) | The study will estimate the effects of rolofylline, alone and in addition to loop diuretic therapy on pulmonary capillary wedge pressure and other hemodynamic parameters, in patients with heart failure and renal impairment. | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Hemodynamic Effects of Rolofylline Injectable Emulsion in the Treatment of Patients With Heart Failure | [
{
"description": "rolofylline placebo IV infusion over 4 hours.",
"name": "Comparator: Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "rolofylline 30 mg IV infusion over 4 hours.",
"name": "rolofylline",
"normalized_type": "3d1aa88... | [
{
"design_group_description": "Placebo",
"design_group_title": "1",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "rolofylline placebo IV infusion over 4 hours.",
... | [
"Heart Failure"
] | [
"Merck Sharp & Dohme Corp."
] | [
"NovaCardia, Inc."
] | [
[
{
"name": "罗咯茶碱",
"lang": "CN"
},
{
"name": "Rolofylline",
"lang": "EN"
}
]
] | null |
NCT06672978 | [
{
"id_field": "org_study_id",
"id_value": [
"ML-VAB-201-3248-2"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2024-516360-29"
]
},
{
"id_domain": "Universal Trial Number",
"id_field": "secondary_id",
"id_type": "Other Ident... | https://clinicaltrials.gov/study/NCT06672978 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis | The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). | A Multi-Center, Open-Label, Single-Arm, Phase 2 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Vabomere (Meropenem-Vaborbactam) In The Treatment Of Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis | [
{
"description": "Administered as specified in the treatment arm",
"name": "Meropenem-Vaborbactam",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Vabomere"
],
"type": "Drug"
},
{
"description": "Administered as prescribed by the study physician in acco... | [
{
"design_group_description": "Participants will receive meropenem-vaborbactam via an IV infusion for a minimum of 3 days, for up to 14 days.<br/>Participants with clinical improvement have the option to switch to an oral antibiotic or home IV therapy after Day 3.",
"design_group_title": "Cohort 1: Age 6 to... | [
"Acute Pyelonephritis",
"Complicated Urinary Tract Infection"
] | [
"Rempex Pharmaceuticals, Inc."
] | [
"Biomedical Advanced Research & Development Authority (Barda)"
] | [
[
{
"name": "美罗培南/韦博巴坦",
"lang": "CN"
},
{
"name": "Meropenem/Vaborbactam",
"lang": "EN"
}
]
] | null |
NCT02051309 | [
{
"id_field": "org_study_id",
"id_value": [
"1110009133_B"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA035001"
]
}
] | https://clinicaltrials.gov/study/NCT02051309 | Guanfacine Clinical Trial for Smoking Cessation | Adult daily smokers motivated to quit smoking will be randomized to extended-release guanfacine (6mg/day) or placebo and will enroll in an 8-week treatment period combining medication with brief behavioral support. The investigators hypothesize that the active dose of guanfacine compared to placebo will increase rates ... | Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation | [
{
"description": "6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.",
"name": "Guanfacine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Guanfacine 6mg/day extended release",
"design_group_title": "Guanfacine 6mg/day ER",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "6mg/day E... | [
"Smoking Cessation"
] | [
"Yale University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸胍法辛",
"lang": "CN"
},
{
"name": "Guanfacine hydrochloride",
"lang": "EN"
},
{
"name": "グアンファシン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00006004 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068012"
]
},
{
"id_field": "secondary_id",
"id_value": [
"E-1599"
]
},
{
"id_field": "secondary_id",
"id_value": [
"E-1599;CDR0000068012"
]
}
] | https://clinicaltrials.gov/study/NCT00006004 | Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating non-small cell lung cancer.<br/>PURPOSE: Randomized ph... | A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients | [
{
"name": "carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": ... | null | [
"Lung Cancer"
] | [
"Eastern Cooperative Oncology Group"
] | [
"National Cancer Institute"
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{... | [
{
"identifier_source": [
{
"code": "a2d25a5a2e538d42da20e4853e8e4885",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a5a5853528555922e2da588ee2a02858",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ECO... |
NCT00539643 | [
{
"id_field": "org_study_id",
"id_value": [
"07-099"
]
}
] | https://clinicaltrials.gov/study/NCT00539643 | Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | The purpose of this study is to evaluate the effect of blocking the blood vessels to the tumor in your liver with small beads alone (Bead Block) versus blocking them with the same bead that contains and releases doxorubicin (a chemotherapy agent). The reason for the study is to see if adding doxorubicin kills more tumo... | A Randomized Single Blind Controlled Trial of Beads vs. Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma (HCC) | [
{
"description": "Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis",
"name": "Bead Block microspheres",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"type": "Device"
},
{
"description": "Bead + Dox Arm: Hepatic arterial... | [
{
"design_group_description": "Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.",
"design_group_title": "Bead Arm",
"design_group_type": "Active Comparator",
"design_group_type_normaliz... | [
"Hepatocellular Carcinoma",
"Liver Cancer",
"Hepatoma"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Columbia University"
] | [
[
{
"name": "盐酸多柔比星",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride",
"lang": "EN"
},
{
"name": "ドキソルビシン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT03171415 | [
{
"id_field": "org_study_id",
"id_value": [
"RZL-012-P2aUS-001"
]
}
] | https://clinicaltrials.gov/study/NCT03171415 | Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers | Obesity is a direct result of food-intake in excess of body energy expenditure. Thus, induction of increased energy expenditure via the activation of thermogenesis at targeted anatomical sites can counterbalance obesity. This trial aims to study RZL-012, a novel compound, in treating obesity by activating thermogenesis... | A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial for the Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers | [
{
"description": "Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.",
"name": "RZL-012",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Subje... | [
{
"design_group_description": "A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):<br/>1. 40mg RZL-012 -administered at 8 sites<br/>2. 80mg RZL-012 - administered at 16 sites<br/>3. 120mg RZL-012 - administered at 24 sites<br/>4. 180mg RZL-012 - ad... | [
"Obesity",
"Weight Loss",
"Overweight and Obesity"
] | [
"Raziel Therapeutics RT Ltd."
] | [
"Spaulding Clinical Research LLC"
] | [
[
{
"name": "RZL-012",
"lang": "EN"
}
]
] | null |
NCT02788786 | [
{
"id_field": "org_study_id",
"id_value": [
"OPP1131701"
]
}
] | https://clinicaltrials.gov/study/NCT02788786 | Feasibility and Acceptability of Use of Daily Oral Rinse in Pregnant Women in Rural Nepal | In Nepal, investigators are conducting a cohort study to estimate the relationship between signs of periodontal disease in pregnant women and preterm delivery. Within that cohort study, investigators plan to conduct an individually randomized trial of the acceptability and effect chlorhexidine, cetylpyridinium chloride... | Feasibility and Acceptability of Daily Oral Rinse in Pregnant Women and Impact on Oral Inflammatory Biomarkers in Rural Nepal | [
{
"description": "non-alcoholic chlorhexidine gluconate antiseptic mouth rinse",
"name": "Chlorhexidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"chlorhexidine oral rinse"
],
"type": "Drug"
},
{
"description": "non-alcoholic cetylpyridinium chlor... | [
{
"design_group_description": "0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks",
"design_group_title": "chlorhexidine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_... | [
"Periodontitis",
"Premature Birth of Newborn"
] | [
"Johns Hopkins Bloomberg School of Public Health"
] | [
"Gates Foundation (United States)"
] | [
[
{
"name": "西吡氯铵",
"lang": "CN"
},
{
"name": "Cetylpyridinium Chloride Hydrate",
"lang": "EN"
},
{
"name": "セチルピリジニウム塩化物水和物",
"lang": "JP"
}
],
[
{
"name": "葡萄糖氯己定",
"lang": "CN"
},
{
"name": "Chlorhexidine gluconate",
... | null |
NCT01032850 | [
{
"id_field": "org_study_id",
"id_value": [
"INST 0820"
]
},
{
"id_domain": "NCI CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-02945"
]
}
] | https://clinicaltrials.gov/study/NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following:<br/>* how effective this combination of study drugs will be in treating HCC<br/>* how long subjects respond to these study drugs<br/>* what types of side effects can be expected, and<br/>* how severe the side effects... | Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | [
{
"description": "Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.",
"name": "Sorafenib & Capecit... | [
{
"design_group_description": "Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)",
"design_group_title": "Arm 1: Sorafenib & Capecitabine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3544... | [
"Hepatocellular Carcinoma"
] | [
"New Mexico Cancer Care Alliance"
] | [
"Bayer AG"
] | [
[
{
"name": "甲苯磺酸索拉非尼",
"lang": "CN"
},
{
"name": "Sorafenib Tosylate",
"lang": "EN"
},
{
"name": "ソラフェニブトシル酸塩",
"lang": "JP"
}
],
[
{
"name": "卡培他滨",
"lang": "CN"
},
{
"name": "Capecitabine",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"code": "2ade328a8a0882e240a899a559822a83",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "9982e945509a58ae2aa29eeeeee09252",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "INS... |
NCT03817411 | [
{
"id_field": "org_study_id",
"id_value": [
"EOC315B2101"
]
}
] | https://clinicaltrials.gov/study/NCT03817411 | Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer | The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib combination in terms of progression-free survival (PFS) in patients previously untreated for advanced HER2 negative advanced gastric or Gast... | A Phase II Randomized Trial of Telatinib in Combination With Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin as First-Line Therapy in Patients With HER2-negative Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction | [
{
"description": "300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.",
"name": "Telatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"EOC315"
],
"type": "Drug"
},
{
"description": "1000 mg/m²,twice daily for 14 days followed by a 7-day rest... | [
{
"design_group_description": "Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.",
"design_group_title": "Telatinib+Capecitabine+Oxal... | [
"Gastric Cancer"
] | [
"EOC Pharma (Thaizhou) Co., Ltd."
] | [
"Zhongshan Hospital Fudan University",
"Shanghai East Hospital"
] | [
[
{
"name": "特拉替尼",
"lang": "CN"
},
{
"name": "Telatinib",
"lang": "EN"
}
],
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
{
"name": "オキサリプラチン",
"lang": "JP"
}
],
[
{
... | null |
NCT03271047 | [
{
"id_field": "org_study_id",
"id_value": [
"ARRAY-162-202"
]
},
{
"id_domain": "Alias Study Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"C4211004"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"i... | https://clinicaltrials.gov/study/NCT03271047 | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with advanced metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease and p... | An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | [
{
"description": "Orally, twice daily.",
"name": "binimetinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intravenously (IV) every 4 weeks (Q4W)",
"name": "nivolumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": ... | [
{
"design_group_description": "binimetinib + nivolumab",
"design_group_title": "Phase 1b / Arm 1A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Orally, twice daily.",
... | [
"MSS",
"RAS-mutant Colorectal Cancer"
] | [
"Pfizer Inc."
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | null |
NCT01323400 | [
{
"id_field": "org_study_id",
"id_value": [
"PAZOGIST"
]
},
{
"id_field": "acronym",
"id_value": [
"PAZOGIST"
]
}
] | https://clinicaltrials.gov/study/NCT01323400 | Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) | The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib. This is a phase II, randomized, multicentre study. | A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib | [
{
"description": "Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.",
"name": "Pazopanib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"desc... | [
{
"design_group_description": "Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.<br/>Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopani... | [
"GIST"
] | [
"Centre Léon Bérard Lyon et Rhône-Alpes"
] | [
"GSK Plc"
] | [
[
{
"name": "培唑帕尼",
"lang": "CN"
},
{
"name": "Pazopanib Hydrochloride",
"lang": "EN"
},
{
"name": "パゾパニブ塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8409e3ea28aa5dae5eaa93ad2a50e884",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e9d942a0899892ee80932d20ee585d85",
"s... |
NCT03660839 | [
{
"id_field": "org_study_id",
"id_value": [
"ACT14655"
]
},
{
"id_domain": "UTN",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"U1111-1191-5573"
]
}
] | https://clinicaltrials.gov/study/NCT03660839 | Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria | Primary Objective:<br/>To show the contribution of artefenomel (OZ439) to the clinical and parasiticidal effect of OZ439/Ferroquine (FQ) combination by analyzing exposure-response of OZ439 measured by Day 28 polymerase chain reaction (PCR)-corrected adequate clinical and parasitological response (ACPR) for the effect a... | A Randomized, Open Label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination With Ferroquine (FQ) and FQ Alone, in African Patients With Uncomplicated Plasmodium Falciparum Mala... | [
{
"description": "Pharmaceutical form: Granules for oral suspension Route of administration: Oral",
"name": "Artefenomel (OZ439)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Pharmaceutical form: Capsule Route of administration: Oral",
"name... | [
{
"design_group_description": "On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.",
"design_group_title": "Ferroquine 400 milligram (mg)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c... | [
"Plasmodium Falciparum Infection"
] | [
"Sanofi"
] | [
"MMV Medicines for Malaria Venture"
] | [
[
{
"name": "Artefenomel Mesylate",
"lang": "EN"
}
],
[
{
"name": "Ferroquine",
"lang": "EN"
}
]
] | null |
NCT06161688 | [
{
"id_field": "org_study_id",
"id_value": [
"23-38752"
]
},
{
"id_field": "acronym",
"id_value": [
"PREVAIL-LC"
]
}
] | https://clinicaltrials.gov/study/NCT06161688 | Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID | Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms... | Placebo-Controlled, Randomized Trial of Ensitrelvir (S-217622) for Viral Persistence and Inflammation in People Experiencing Long COVID (PREVAIL-LC) | [
{
"description": "Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days",
"name": "Ensitrelvir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ensitrelvir fumaric acid"
],
"type": "Drug"
},
{
"... | [
{
"design_group_description": "Ensitrelvir fumaric acid (S-217622) given orally 375 mg on day 1 followed by 125 mg daily for 4 additional days",
"design_group_title": "Ensitrelvir (S-217622)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",... | [
"Long COVID",
"Post Acute Sequelae of COVID-19",
"Post-Acute COVID-19"
] | [
"The University of California, San Francisco"
] | [
"Shionogi, Inc."
] | [
[
{
"name": "恩赛特韦",
"lang": "CN"
},
{
"name": "Ensitrelvir Fumaric Acid",
"lang": "EN"
},
{
"name": "エンシトレルビル フマル酸",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8439a3293523ea322ea2595444aaa92e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PREVAIL-LC"
}
] |
NCT03511391 | [
{
"id_field": "org_study_id",
"id_value": [
"EC2017/1678"
]
},
{
"id_field": "acronym",
"id_value": [
"CHEERS"
]
}
] | https://clinicaltrials.gov/study/NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | This randomized controlled phase II trial will investigate whether the addition of stereotactic body radiotherapy to checkpoint inhibitor treatment in patients with non-small-cell lung carcinoma, urothelial carcinoma, renal cell carcinoma, melanoma or head-and-neck carcinoma can improve progression-free survival as com... | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors: CHEERS-trial | [
{
"description": "per national standard of care",
"name": "Nivolumab or Pembrolizumab or Atezolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Immune checkpoint inhibitor"
],
"type": "Drug"
},
{
"description": "Stereotactic body radiotherapy is ... | [
{
"design_group_description": "Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:<br/>Nivolumab or Pembrolizumab or Atezolizumab + SBRT",
"design_group_title": "Experimental arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f... | [
"Urothelial Carcinoma",
"Melanoma",
"Renal Cell Carcinoma",
"Non-small Cell Lung Cancer",
"Head and Neck Cancer"
] | [
"Ghent University Hospital"
] | [
"Az Sint-Lucas Gent",
"AZ Sint Lucas Brugge",
"Jules Bordet Institute"
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CHEERS"
}
] |
NCT03012581 | [
{
"id_field": "org_study_id",
"id_value": [
"UC-0105/1611"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2016-002257-37"
]
},
{
"id_field": "acronym",
"id_value": [
"AcSé"
]
}
] | https://clinicaltrials.gov/study/NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard ... | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | [
{
"description": "Treatment",
"name": "Nivolumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Opdivo"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Nivolumab 240 mg IV over 60 minutes every 14 days.",
"design_group_title": "Nivolumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Treatm... | [
"Carcinoma, Renal Cell",
"Head and Neck Neoplasm",
"Skin Neoplasms",
"Microsatellite Instability",
"Penile Neoplasms",
"Cancer With POLE Exonucleasic Domain Mutation"
] | [
"UNICANCER"
] | [
"National Cancer Institute",
"Ligue Contre Le Cancer",
"Bristol Myers Squibb Co."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "dd35a20e2e922d25a48ea50aea2552dd",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "AcSé"
},
{
"identifier_source": [
{
... |
NCT02077998 | [
{
"id_field": "org_study_id",
"id_value": [
"UCDCC#237"
]
},
{
"id_domain": "UC Davis",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"457404"
]
},
{
"id_domain": "University of California, Davis",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT02077998 | Oxaliplatin in Treating Patients With Metastatic Breast Cancer | This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and blood and the side effects and how well oxaliplatin works in treating patients with metastatic breast cancer. DNA analysis of tumor tissue and blood samples from patients receiving carbon C 14 oxaliplatin may help doctors predict ho... | A Diagnostic Feasibility Trial of a [14C]Oxaliplatin Microdosing Assay for Prediction of Chemoresistance to Oxaliplatin Chemotherapy | [
{
"description": "Given IV",
"name": "carbon C 14 oxaliplatin",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"other_name": [
"[14C] oxaliplatin"
],
"type": "Radiation"
},
{
"description": "Given IV",
"name": "oxaliplatin",
"normalized_type": "3d1aa88261d64c038... | [
{
"design_group_description": "PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.<br/>PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Diagnostic (... | [
"Stage IV Breast Cancer"
] | [
"University of California, Davis"
] | [
"National Cancer Institute"
] | [
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
{
"name": "オキサリプラチン",
"lang": "JP"
}
]
] | null |
NCT01836068 | [
{
"id_field": "org_study_id",
"id_value": [
"J1331"
]
},
{
"id_domain": "Johns Hopkins",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NA_00083734"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id... | https://clinicaltrials.gov/study/NCT01836068 | Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals | To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant | Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals | [
{
"description": "Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions",
"name": "Enfuvirtide",
... | [
{
"design_group_description": "Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavi... | [
"HIV"
] | [
"The Sidney Kimmel Comprehensive Cancer Center"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "恩夫韦肽",
"lang": "CN"
},
{
"name": "Enfuvirtide",
"lang": "EN"
}
]
] | null |
NCT02420665 | [
{
"id_field": "org_study_id",
"id_value": [
"2014-0368"
]
},
{
"id_domain": "NCI",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"HHSN261200800001E"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract... | https://clinicaltrials.gov/study/NCT02420665 | Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia | The goal of this clinical research study is to compare a type of imaging called high-resolution microendoscopy (HRME) for detecting abnormal tissue in the cervix to the standard of care, which is visual inspection with acetic acid (VIA) with a colposcopy procedure. Researchers also want to learn if HRME images can show... | Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia | [
{
"description": "0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.",
"name": "Proflavine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "HRME images obtained from one visually normal cervical sit... | [
{
"design_group_description": "Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images o... | [
"Cervical Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute",
"National Institutes of Health"
] | [
[
{
"name": "酢酸",
"lang": "CN"
},
{
"name": "Acetic Acid, Glacial",
"lang": "EN"
},
{
"name": "氷酢酸",
"lang": "JP"
}
],
[
{
"name": "原黄素",
"lang": "CN"
},
{
"name": "Proflavine",
"lang": "EN"
}
]
] | null |
NCT05490264 | [
{
"id_field": "org_study_id",
"id_value": [
"SN-2022-01"
]
}
] | https://clinicaltrials.gov/study/NCT05490264 | [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors | The purpose of this study is to evaluate the safety of [68Ga]Ga-NOTA-SNA002 and investigate the uptake of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors. | [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors | [
{
"description": "[68Ga]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography",
"name": "[68Ga]Ga-NOTA-SNA002",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "A dose of 1mCi-5mCi of [68Ga]Ga-NOTA-SNA002 between 0.1mg to 0.9mg will be administered intravenously over 5minutes in Day 1 of subject enrollment",
"design_group_title": "[68Ga]Ga-NOTA-SNA002",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "7... | [
"Solid Tumor",
"Positron-Emission Tomography(PET)"
] | [
"Suzhou SmartNuclide Biopharmaceutical Co., Ltd."
] | [
"The First Affiliated Hospital of Soochow University"
] | [
[
{
"name": "镓[68Ga]纳坦重组PD-L1单域抗体(Suzhou SmartNuclide Biopharmaceutical)",
"lang": "CN"
},
{
"name": "[68Ga] anti-PD-L1 nanobody(Suzhou SmartNuclide Biopharmaceutical)",
"lang": "EN"
}
]
] | null |
NCT02382549 | [
{
"id_field": "org_study_id",
"id_value": [
"17700"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01CA178846"
]
},
{
"id_field": "acronym",
"id_value": [
"Mel61"
]
}
] | https://clinicaltrials.gov/study/NCT02382549 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by performing tests in ... | A TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A HELPER PEPTIDE VACCINE PLUS COMBINATION OF BRAF INHIBITION AND MEK INHIBITION (MEL61) | [
{
"description": "BRAF inhibitor",
"name": "BRAF inhibitor",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides",
"name": "6MHP",
"normalized_type": "30faef638ae74... | [
{
"design_group_description": "The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines a... | [
"Melanoma"
] | [
"University of Virginia"
] | [
"National Cancer Institute"
] | [
[
{
"name": "6-melanoma helper peptide vaccine(University of Virginia)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Mel61"
}
] |
NCT04230681 | [
{
"id_field": "org_study_id",
"id_value": [
"201912042"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UL1TR002345"
]
}
] | https://clinicaltrials.gov/study/NCT04230681 | Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery | A RCT to compare hydromorphone versus fentanyl for pain control following tonsillectomy or adenotonsillectomy surgery. | A Randomized Controlled Trial to Compare Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery | [
{
"description": "Patients will be randomized to one of two opioids for the treatment of post-operative pain.",
"name": "Hydromorphone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Fentanyl",
"name": "Fentanyl",
"normalized_type": "3d1aa... | [
{
"design_group_title": "Fentanyl",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Fentanyl",
"intervention_name": "Fentanyl",
"intervention_type": "Drug",... | [
"Obstructive Sleep Apnea",
"Tonsillitis"
] | [
"Washington University School of Medicine"
] | [
"National Center for Advancing Translational Sciences"
] | [
[
{
"name": "枸橼酸芬太尼",
"lang": "CN"
},
{
"name": "Fentanyl Citrate",
"lang": "EN"
},
{
"name": "フェンタニルクエン酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸氢吗啡酮",
"lang": "CN"
},
{
"name": "Hydromorphone Hydrochloride",
"lang": "E... | null |
NCT03968913 | [
{
"id_field": "org_study_id",
"id_value": [
"19-000724"
]
}
] | https://clinicaltrials.gov/study/NCT03968913 | Biologic Therapy to Prevent Osteoarthritis After ACL Injury | Anterior cruciate ligament (ACL) injuries are extremely common. On average, 50% of individuals suffering an ACL injury will develop radiographic osteoarthritis (OA) 10 to 20 years after injury. Unfortunately, ACL reconstruction does not prevent risk of future OA.<br/>Interleukin-1 (IL-1) levels in the human knee joint ... | Biologic Therapy to Prevent Osteoarthritis After ACL Injury | [
{
"description": "anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint",
"name": "Anakinra injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Kineret"
],
"type": "Drug"
},
{
"description": "5 milliliters of steri... | [
{
"design_group_description": "Subjects will receive two injections of sterile saline after ACL injury, prior to surgery",
"design_group_title": "Control",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
... | [
"Anterior Cruciate Ligament Injuries"
] | [
"University of California, Los Angeles"
] | [
"Orthopedic Education Inc"
] | [
[
{
"name": "安纳白介素",
"lang": "CN"
},
{
"name": "Anakinra (Amgen)",
"lang": "EN"
}
]
] | null |
NCT01843855 | [
{
"id_field": "org_study_id",
"id_value": [
"11-000161"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK082396"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UL1RR... | https://clinicaltrials.gov/study/NCT01843855 | The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass | The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypas... | The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass | [
{
"description": "Exendin 9,39 is a competitive antagonist of endogenous GLP-1.",
"name": "Exendin 9,39",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "A saline infusion will be given to match the study drug infusion.",
"name": "Placebo",
... | [
{
"design_group_description": "Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.",
"design_group_title": "Exendin 9,39",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"Type 2 Diabetes Mellitus"
] | [
"Mayo Clinic"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"National Center for Research Resources"
] | [
[
{
"name": "Avexitide",
"lang": "EN"
}
]
] | null |
NCT02414932 | [
{
"id_field": "org_study_id",
"id_value": [
"SPUH 05/14"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-004262-14"
]
},
{
"id_field": "acronym",
"id_value": [
"KEEP-WELL"
]
}
] | https://clinicaltrials.gov/study/NCT02414932 | Ketamine for Depression Relapse Prevention Following ECT | Depression affects up to 20% of people in their lifetime and can be a severe debilitating illness. Indeed, the World Health Organisation has estimated that depression will soon be the second leading contributor to the burden of disease worldwide. One of the big problems for patients and doctors is that currently availa... | Ketamine for Depression Relapse Prevention Following ECT: a Randomised Pilot Trial With Blood Biomarker Evaluation | [
{
"description": "Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland",
"name": "Ketamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ketalar"
],
"type": "Drug"
},
{
"description": "Midazolam 0.045 mg/kg; Roche Products Ireland Ltd",
"n... | [
{
"design_group_description": "Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. ... | [
"Depression"
] | [
"St. Patrick's University Hospital"
] | [
"Health Research Board"
] | [
[
{
"name": "盐酸氯胺酮",
"lang": "CN"
},
{
"name": "Ketamine Hydrochloride",
"lang": "EN"
},
{
"name": "ケタミン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "888ea2e54adaa3929a5a92de80e9e499",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "KEEP-WELL"
}
] |
NCT01184885 | [
{
"id_field": "org_study_id",
"id_value": [
"09G.474"
]
},
{
"id_domain": "CCRRC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2009-35"
]
},
{
"id_domain": "JeffTrial Number",
"id_field": "secondary_id",
"id_type": "Other ... | https://clinicaltrials.gov/study/NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD (Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicine and Dexamethasone), with an ultimate goal to perform a phase II study to evaluate r... | A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies | [
{
"description": "* Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.<br/>* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 5... | [
{
"design_group_description": "Hyper-CVAD and Sirolimus",
"design_group_title": "Hyper-CVAD and Sirolimus",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "* Cycle A: Cyclop... | [
"Lymphoid Malignancies (New or Relapsed)",
"Acute Lymphoblastic Leukemia",
"Burkitt Lymphoma",
"Lymphoblastic Lymphoma",
"Mantle Cell Lymphoma",
"Adult T-cell Leukemia/Lymphoma"
] | [
"Sidney Kimmel Cancer Center at Thomas Jefferson University"
] | [
"American Society of Clinical Oncology, Inc."
] | [
[
{
"name": "西罗莫司",
"lang": "CN"
},
{
"name": "Sirolimus",
"lang": "EN"
},
{
"name": "シロリムス",
"lang": "JP"
}
]
] | null |
NCT06511037 | [
{
"id_field": "org_study_id",
"id_value": [
"4951"
]
},
{
"id_domain": "UCI CFCCC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"UCI 23-184"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCI 23-184;4951"
]
}
] | https://clinicaltrials.gov/study/NCT06511037 | PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery. | The Impact of Pafolacianine Injection for Intraoperative Imaging on Outcomes of Gastrointestinal Cancer Peritoneal Carcinomatosis - A Pilot Study | [
{
"description": "Given IV",
"name": "Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "All subjects will receive one single intravenous infusion of 0.025 mg/kg of pafolacianine (CYTALUX) injection prior to anticipated intraoperative imaging planned for cytoreductive surgery.",
"design_group_title": "Pafolacianine (CYTALUX)",
"design_group_type": "Experimenta... | [
"Gastrointestinal Cancer",
"Peritoneal Carcinomatosis"
] | [
"University of California, Irvine"
] | [
"On Target Laboratories, Inc."
] | [
[
{
"name": "Pafolacianine",
"lang": "EN"
}
]
] | null |
NCT03079921 | [
{
"id_field": "org_study_id",
"id_value": [
"826386"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"2R01DK091331-06"
]
}
] | https://clinicaltrials.gov/study/NCT03079921 | Adrenergic System in Islet Transplantation | To determine the effect of sympathetic neural and hormonal (epinephrine) input on islet cell hormonal responses to insulin-induced hypoglycemia in type 1 diabetic recipients of intrahepatic islet transplantation. We hypothesize that α-adrenergic (neural) blockage will abolish insulin-mediated suppression of C-peptide, ... | Adrenergic Contribution to Glucose Counterregulation in Islet Transplantation | [
{
"description": "Physiologic receptor blockade (α1-receptor).",
"name": "Phentolamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Regitine"
],
"type": "Drug"
},
{
"description": "Physiologic receptor blockade (β2-receptor).",
"name": "Proprano... | [
{
"design_group_description": "The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 m... | [
"Type1diabetes",
"Hypoglycemia",
"Hypoglycemia Unawareness",
"Islet Cell Transplantation"
] | [
"University of Pennsylvania"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"National Institutes of Health"
] | [
[
{
"name": "甲磺酸酚妥拉明",
"lang": "CN"
},
{
"name": "Phentolamine Mesylate",
"lang": "EN"
},
{
"name": "フェントラミンメシル酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸普萘洛尔",
"lang": "CN"
},
{
"name": "Propranolol Hydrochloride",
"lang... | null |
NCT06656702 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00408938"
]
},
{
"id_field": "secondary_id",
"id_value": [
"IRB00408938"
]
}
] | https://clinicaltrials.gov/study/NCT06656702 | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | [
{
"description": "Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.",
"name": "Psilocybin",
"normalized_typ... | [
{
"design_group_description": "All subjects will be in the same, open label arm",
"design_group_title": "Psilocybin",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment inc... | [
"Amyotrophic Lateral Sclerosis"
] | [
"The Johns Hopkins University"
] | [
"Defense Language Institute Foreign Language Center"
] | [
[
{
"name": "裸盖菇素",
"lang": "CN"
},
{
"name": "Psilocybin",
"lang": "EN"
}
]
] | null |
NCT05530655 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00007510_URGUP23077"
]
},
{
"id_field": "secondary_id",
"id_value": [
"STUDY00007510_URGUP23077"
]
}
] | https://clinicaltrials.gov/study/NCT05530655 | A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer | This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms. | A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer | [
{
"description": "This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.",
"name": "Lisinopril Tablets",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients who receive radiation but no intervention",
"design_group_title": "Control group",
"design_group_type": "No Intervention"
},
{
"design_group_title": "Intervention group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b... | [
"Prostate Cancer",
"Radiation Toxicity",
"Urinary Complication"
] | [
"University of Rochester"
] | [
"Medical College of Wisconsin"
] | [
[
{
"name": "赖诺普利",
"lang": "CN"
},
{
"name": "Lisinopril",
"lang": "EN"
},
{
"name": "リシノプリル水和物",
"lang": "JP"
}
]
] | null |
NCT03678012 | [
{
"id_field": "org_study_id",
"id_value": [
"1802077294"
]
}
] | https://clinicaltrials.gov/study/NCT03678012 | Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model | To evaluate the effects of a clinically approved and commercially available iron oxide formulation Ferumoxytol (Feraheme®) to control cariogenic biofilms and enamel demineralization. This study will be testing topical application of Ferumoxytol extra-orally using a standard in situ biofilm demineralization model. | Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model | [
{
"description": "1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.",
"name": "Ferumoxytol/Hydrogen peroxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio",
"design_group_title": "Ferumoxytol/Hydrogen peroxide",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"int... | [
"Dental Caries"
] | [
"University of Pennsylvania"
] | [
"Indiana University"
] | [
[
{
"name": "非莫妥尔",
"lang": "CN"
},
{
"name": "Ferumoxytol",
"lang": "EN"
}
],
[
{
"name": "过氧化氢",
"lang": "CN"
},
{
"name": "Hydrogen Peroxide",
"lang": "EN"
},
{
"name": "過酸化水素",
"lang": "JP"
}
]
] | null |
NCT01856790 | [
{
"id_field": "org_study_id",
"id_value": [
"1211011156"
]
}
] | https://clinicaltrials.gov/study/NCT01856790 | Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes | "Closed loop artificial pancreas" systems have been under development for the control of blood sugars in those living with diabetes. These systems consist of a continuous glucose sensor, which sends a signal to a computer program that automatically determines how much insulin to give. The computer program then tells an... | Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes | [
{
"description": "Insulin pump controlled by closed loop unit and algorithm",
"name": "ePID closed loop system",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"type": "Device"
},
{
"description": "Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that work... | [
{
"design_group_description": "Each participant recruited into the study will undergo two inpatient closed loop admissions.<br/>The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-i... | [
"Type 1 Diabetes"
] | [
"Yale University"
] | [
"Yale University",
"Juvenile Diabetes Research Foundation"
] | [
[
{
"name": "利拉鲁肽",
"lang": "CN"
},
{
"name": "Liraglutide",
"lang": "EN"
},
{
"name": "リラグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT05085431 | [
{
"id_field": "org_study_id",
"id_value": [
"CD19/BCMA-003"
]
}
] | https://clinicaltrials.gov/study/NCT05085431 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome | [
{
"description": "Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection",
"name": "Assigned Interventions CD19/BCMA CAR T-cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.",
"design_group_title": "Treatment of Sjogren's Syndrome",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f... | [
"Sjogren's Syndrome",
"Autoimmune Diseases"
] | [
"Zhejiang University"
] | [
"Shanghai Yake Biotechnology Co., Ltd"
] | [
[
{
"name": "CD19/BCMA CAR Tcells therapy (Yake Biotechnology)",
"lang": "EN"
}
]
] | null |
NCT00278369 | [
{
"id_field": "org_study_id",
"id_value": [
"NU 04U1"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA060553"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NU-04U1"
]
},
{
"id_domain": "Northwe... | https://clinicaltrials.gov/study/NCT00278369 | Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer | RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry tumor-killing substances directly to kidney cancer cells. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving denileukin diftitox together with interleukin-2 may kill more tumor cells.<br/>PURP... | A Pilot Study of Denileukin Diftitox in Combination With High-Dose IL-2 for Patients With Metastatic Renal Cell Carcinoma | [
{
"description": "The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin... | [
{
"design_group_description": "6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Kidney Cancer"
] | [
"Northwestern University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "地尼白介素2",
"lang": "CN"
},
{
"name": "Denileukin Diftitox",
"lang": "EN"
},
{
"name": "デニロイキン ジフチトクス（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿地白介素",
"lang": "CN"
},
{
"name": "Aldesleukin",
"lang": "EN"
... | null |
NCT07021430 | [
{
"id_field": "org_study_id",
"id_value": [
"24-3166"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21AI180728"
]
},
{
"id_field": "secondary_id",
"id_value": [
"R21AI180728;24-3166"
]
}
] | https://clinicaltrials.gov/study/NCT07021430 | Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy | The purpose of this study is to demonstrate the feasibility, acceptability, and preliminary effectiveness of a focal mass drug administration program for household members of pregnant women to protect against malaria in pregnancy. | Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy: a Pilot Randomized Controlled Trial | [
{
"description": "A single or monthly dose of Dihydroartemisinin Piperaquine based on weight will be taken orally.",
"name": "Dihydroartemisinin Piperaquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Focal Mass Drug Administration"
],
"type": "Drug"
}
] | [
{
"design_group_description": "A single administration of Dihydroartemisinin Piperaquine as a focal mass drug administration Focal Mass Drug Administration.",
"design_group_title": "A single dose of Dihydroartemisinin Piperaquine",
"design_group_type": "Experimental",
"design_group_type_normalized_i... | [
"Malaria Prevention"
] | [
"The University of North Carolina at Chapel Hill"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "双氢青蒿素哌喹",
"lang": "CN"
},
{
"name": "Piperaquine tetraphosphate/Artenimol",
"lang": "EN"
}
]
] | null |
NCT05686967 | [
{
"id_field": "org_study_id",
"id_value": [
"22-1521"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R56AG072094"
]
},
{
"id_field": "acronym",
"id_value": [
"MITO-STEP"
]
}
] | https://clinicaltrials.gov/study/NCT05686967 | MitoQ and Exercise Effects on Vascular Health | An impairment in vascular function can lead to the development of age-associated cardiovascular disease (CVD), the leading cause of death in postmenopausal women. Regular aerobic exercise (AE) benefits vascular function in older men by reducing oxidative stress, however, similar AE training improvements are diminished ... | MitoQ Supplementation for Restoring Aerobic Exercise Training Effects on Endothelial Function in Postmenopausal Women | [
{
"description": "MitoQ is a biochemically modified form of ubiquinol",
"name": "MitoQ",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"other_name": [
"Mitoquinol"
],
"type": "Dietary Supplement"
},
{
"description": "Each placebo capsule contains inert excipient and is... | [
{
"design_group_description": "Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus experimental MitoQ, 20mg/d.<br/>Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.",
"design_group_... | [
"Aging",
"Menopause"
] | [
"University of Colorado Denver"
] | [
"National Institute on Aging"
] | [
[
{
"name": "Mitoquinone mesylate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MITO-STEP"
}
] |
NCT02228031 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-00059904"
]
}
] | https://clinicaltrials.gov/study/NCT02228031 | Oxytocin, Emotions and Mirror Neurons | The purpose of this project is to investigate the possible effect of intranasally administered Oxytocin (OT) on specific mirror neuron areas in human brain. The mirror neuron system (MNS) is thought to be involved in action perception and understanding, and may also underlie more complex cognitive processes such as imi... | The Influence of Oxytocin on the Mirror Neuron System: Developing Brain Imaging Paradigms for Future Therapeutic Interventions | [
{
"description": "The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session",
"name": "Oxytocin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name"... | [
{
"design_group_description": "The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.",
"design_group_title": "Oxytocin",
"design_group_type": "Experimental",
"d... | [
"Social Cognition",
"Expressed Emotion"
] | [
"University of Maryland Baltimore"
] | [
"University of Maryland"
] | [
[
{
"name": "缩宫素",
"lang": "CN"
},
{
"name": "Oxytocin",
"lang": "EN"
},
{
"name": "オキシトシン",
"lang": "JP"
}
]
] | null |
NCT04134325 | [
{
"id_field": "org_study_id",
"id_value": [
"LCCC1852-ATL"
]
}
] | https://clinicaltrials.gov/study/NCT04134325 | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymp... | A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma | [
{
"description": "Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells",
"name": "Nivolumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Opdivo"
],
"type": "Biological"
},... | [
{
"design_group_description": "Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the disc... | [
"Relapsed Hodgkin Lymphoma",
"Refractory Hodgkin Lymphoma"
] | [
"Lineberger Comprehensive Cancer Center"
] | [
"American Society of Clinical Oncology, Inc."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
... | null |
NCT04532268 | [
{
"id_field": "org_study_id",
"id_value": [
"hCD19-001"
]
}
] | https://clinicaltrials.gov/study/NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma. | Clinical Trial for the Safety and Efficacy of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma | [
{
"description": "Each subject receive humanized CD19 CAR T-cells by intravenous infusion",
"name": "Humanized CD19 CAR-T cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Humanized CD19 CAR-T cells injection"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.",
"design_group_title": "Administration of Humanized CD19 CAR T-cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b... | [
"Acute Lymphoblastic Leukemia",
"Non-hodgkin Lymphoma,B Cell"
] | [
"Zhejiang University"
] | [
"Shanghai Yake Biotechnology Co., Ltd"
] | [
[
{
"name": "Anti-CD19 CART cell therapy (YaKe Biotechnology)",
"lang": "EN"
}
]
] | null |
NCT02754856 | [
{
"id_field": "org_study_id",
"id_value": [
"2015-0828"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-00772"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT02754856 | Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery | This phase I trial studies the side effects and how well tremelimumab and durvalumab work in treating patients with colorectal cancer that has spread to the liver and can be removed by surgery. Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body's immune system attack the ca... | Pilot Study Assessing the Safety and Tolerability of the Neoadjuvant Use of Tremelimumab (Anti-CTLA-4) Plus Durvalumab (MEDI4736) (Anti-PD-L1) in the Treatment of Resectable Colorectal Cancer Liver Metastases | [
{
"description": "Given IV",
"name": "Durvalumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Imfinzi",
"Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer",
... | [
{
"design_group_description": "Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.",
"design_group_title": "Treatment (tremelimuma... | [
"Metastatic Carcinoma in the Liver",
"Resectable Mass",
"Stage IV Colorectal Cancer AJCC v7",
"Stage IVA Colorectal Cancer AJCC v7",
"Stage IVB Colorectal Cancer AJCC v7"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "曲麦利尤单抗",
"lang": "CN"
},
{
"name": "Tremelimumab",
"lang": "EN"
},
{
"name": "トレメリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "度伐利尤单抗",
"lang": "CN"
},
{
"name": "Durvalumab",
"lang": "EN"
},
{
... | null |
NCT00995826 | [
{
"id_field": "org_study_id",
"id_value": [
"08-0002"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1UC1AI062373-01"
]
},
{
"id_domain": "NIAID DMID",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Num... | https://clinicaltrials.gov/study/NCT00995826 | Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958 | The purpose of this study is to test the safety and tolerability of an investigational multi-dose inhaled flu medication, CS-8958. Study participants will include 16 males and females, aged 18-55 years of age, inclusive. Participants will be divided into two treatment groups (Groups A and B) with each group consisting ... | CS-8958 - A Phase I, Double-blind, Placebo-controlled, Ascending, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects. | [
{
"description": "Inhaled CS-8958",
"name": "CS-8958",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Laninamivir"
],
"type": "Drug"
},
{
"description": "Inhaled placebo",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",... | [
{
"design_group_title": "placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Inhaled placebo",
"intervention_name": "Placebo",
"intervention_type": "... | [
"Influenza"
] | [
"Biota Scientific Management Pty Ltd."
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "辛酸拉尼米韦",
"lang": "CN"
},
{
"name": "Laninamivir Octanoate Hydrate",
"lang": "EN"
},
{
"name": "ラニナミビルオクタン酸エステル水和物",
"lang": "JP"
}
]
] | null |
NCT01091077 | [
{
"id_field": "org_study_id",
"id_value": [
"GFN-001"
]
}
] | https://clinicaltrials.gov/study/NCT01091077 | A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection | Hepatitis C virus when it leaves the cells in the liver is bound to a type of fat. An component of grapefruit could block this fat and thus lower the amount of virus in the blood stream. We propose that treatment with this ingredient, called naringenin, could be used to block this fat and HCV in persons infected with h... | A Pilot Study of the Grapefruit Flavonoid Naringenin for the Treatment of HCV Infection | [
{
"description": "1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water",
"name": "Naringenin",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"other_name": [
"Grapefruit"
],
"type": "Dietary Supplement"
}
] | [
{
"design_group_description": "Single dose of naringenin, compared to placebo in the same individual.",
"design_group_title": "Naringenin",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"interve... | [
"Hepatitis C Virus",
"HCV Infection",
"Chronic HCV",
"Hepatitis C"
] | [
"The General Hospital Corp."
] | [
"Harvard University"
] | [
[
{
"name": "柚皮素",
"lang": "CN"
},
{
"name": "Naringenin",
"lang": "EN"
}
]
] | null |
NCT07323173 | [
{
"id_field": "org_study_id",
"id_value": [
"LBL-047-CN001"
]
}
] | https://clinicaltrials.gov/study/NCT07323173 | A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus | A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients with systemic lupus erythematosus. | A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus | [
{
"description": "Single subcutaneous injection",
"name": "LBL-047 for Injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LBL-047"
],
"type": "Drug"
},
{
"description": "Single subcutaneous injection",
"name": "LBL-047 placebo for injection"... | [
{
"design_group_description": "LBL-047 for Injection,Single subcutaneous injection.",
"design_group_title": "LBL-047 for Injection",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descrip... | [
"Systemic Lupus Erythematosus"
] | [
"Nanjing Leads Biolabs Co., Ltd."
] | [
"Shanghai Public Health Clinical Center"
] | [
[
{
"name": "LBL-047",
"lang": "EN"
}
]
] | null |
NCT02337270 | [
{
"id_field": "org_study_id",
"id_value": [
"M002"
]
}
] | https://clinicaltrials.gov/study/NCT02337270 | Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol | This is a phase 1 study, in healthy volunteers who have previously been immunized with bacilli Calmette Guerin (BCG), to evaluate the safety and immune responses that develop in the blood and lungs following the administration by aerosol of a new experimental adenovirus-based vaccine for tuberculosis (TB), Ad5Ag85A. | Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol | [
{
"description": "Aerosol administration of Ad5Ag85A",
"name": "Ad5Ag85A",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Receive 10^6 Ad5Ag85A by aerosol at day 0",
"design_group_title": "Group 1 Aerosol",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Aerosol a... | [
"Tuberculosis"
] | [
"McMaster University"
] | [
"Canadian Institutes of Health Research"
] | [
[
{
"name": "Ad5-Ag85A",
"lang": "EN"
}
]
] | null |
NCT06934447 | [
{
"id_field": "org_study_id",
"id_value": [
"PBC088"
]
}
] | https://clinicaltrials.gov/study/NCT06934447 | Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE | This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of refractory systemic lupus erythematosus. | Study of BCMA/CD70 Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Childhood-oneset Systemic Lupus Erythematosus | [
{
"description": "Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.",
"name": "anti-BCMA/CD70-CAR-T cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "This trial was designed as an open, single-arm, multicenter, dose-increasing trial.",
"design_group_title": "CAR-T treatment group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"CAR T Cell Therapy",
"Systemic Lupus Erythematosus",
"BCMA"
] | [
"The Children's Hospital of Zhejiang University School of Medicine"
] | [
"Chongqing Precision Biotechnology Co., Ltd."
] | [
[
{
"name": "Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)",
"lang": "EN"
}
]
] | null |
NCT04616248 | [
{
"id_field": "org_study_id",
"id_value": [
"1B-22-2"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2022-07303"
]
},
{
"id_domain": "University of Southern Califo... | https://clinicaltrials.gov/study/NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | This phase I trial evaluates the safety and effectiveness of in situ immunomodulation with CDX-301, radiotherapy, CDX-1140 and Poly-ICLC (Cohort A) and these with intravenous (IV) pembrolizumab and subcutaneous (SC) tocilizumab (Cohort B) in treating patients with unresectable and measurable metastatic melanoma, cutane... | A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease | [
{
"description": "Given IT",
"name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Agonist CD40 Antibody CDX-1140",
"Anti-CD40 Agonistic Monoclonal Antibody CDX-1140",
"CDX 1140",
"CDX-1140"
],
... | [
{
"design_group_description": "Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease pr... | [
"Anatomic Stage IV Breast Cancer AJCC v8",
"Metastatic Breast Carcinoma",
"Prognostic Stage IV Breast Cancer AJCC v8",
"Unresectable Breast Carcinoma",
"Metastatic Melanoma",
"Unresectable Melanoma",
"Cutaneous Squamous Cell Carcinoma",
"Merkel Cell Carcinoma",
"Soft Tissue Sarcoma",
"Bone Sarcoma... | [
"University of Southern California"
] | [
"National Institutes of Health"
] | [
[
{
"name": "聚肌胞",
"lang": "CN"
},
{
"name": "Poly ICLC",
"lang": "EN"
}
],
[
{
"name": "CDX-1140",
"lang": "EN"
}
],
[
{
"name": "托珠单抗",
"lang": "CN"
},
{
"name": "Tocilizumab",
"lang": "EN"
},
{
"... | null |
NCT03383692 | [
{
"id_field": "org_study_id",
"id_value": [
"DS8201-A-A104"
]
},
{
"id_domain": "JAPIC CTI",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"173790"
]
}
] | https://clinicaltrials.gov/study/NCT03383692 | Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells. This study will test an experimental drug called DS-8201a that has not been approved by the health authorities yet.<br/>DS-8201a will be tested for... | A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors | [
{
"description": "DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution",
"name": "DS-8201a",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Ritona... | [
{
"design_group_description": "DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3",
"design_group_title": "Cohort 1: DS-8201a + Ritonavir",
"design_group_type": "Experimental",
"design_grou... | [
"Neoplasm Metastasis"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "伊曲康唑",
"lang": "CN"
},
{
"name": "Itraconazole",
"lang": "EN"
},
{
"name": "イトラコナゾール",
"lang": "JP"
}
],
[
{
"name": "德曲妥珠单抗",
"lang": "CN"
},
{
"name": "Fam-trastuzumab deruxtecan-NXKI",
"lang": "EN"
... | null |
NCT02121509 | [
{
"id_field": "org_study_id",
"id_value": [
"1288.10"
]
},
{
"id_domain": "EudraCT",
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2013-005143-85"
]
}
] | https://clinicaltrials.gov/study/NCT02121509 | Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects | The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and metformin extended release. | Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/750 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial) | [
{
"description": "1 x Linagliptin tablet",
"name": "Linagliptin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2 x Linagliptin/Metformin ER FDC tablet",
"name": "Linagliptin/Metformin ER FDC",
"normalized_type": "3d1aa88261d64c03841372397... | [
{
"design_group_description": "Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition",
"design_group_title": "FDC first, fasted",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"inter... | [
"Healthy"
] | [
"Boehringer Ingelheim GmbH"
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "利格列汀",
"lang": "CN"
},
{
"name": "Linagliptin",
"lang": "EN"
},
{
"name": "リナグリプチン",
"lang": "JP"
}
],
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{... | null |
NCT03927573 | [
{
"id_field": "org_study_id",
"id_value": [
"GEM3PSCA-01"
]
}
] | https://clinicaltrials.gov/study/NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to respond to standard therapy. | A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker | [
{
"description": "Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles",
"name": "GEM3PSCA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells",
"design_group_title": "GEM3PSCA",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interven... | [
"Non-small Cell Lung Cancer",
"Prostate Cancer",
"Renal Cancer",
"Transitional Cell Carcinoma"
] | [
"AvenCell Europe GmbH"
] | [
"GCP Service International Ltd & Co KG"
] | [
[
{
"name": "GEM3-PSCA",
"lang": "EN"
}
]
] | null |
NCT00016185 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068605"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA022453"
]
},
{
"id_field": "secondary_id",
"id_value": [
"WSU-C-2197"
]
},
{
"id_field": ... | https://clinicaltrials.gov/study/NCT00016185 | Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.<br/>PURPOSE: Phase I trial to study the effectiveness of combining flavopiridol and docetaxel in treating patients who have advanced solid tumor... | Phase I Study Of Flavopiridol And Docetaxel (Taxotere) In Patients With Advanced Cancers | [
{
"name": "alvocidib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"Barbara Ann Karmanos Cancer Institute"
] | [
"National Cancer Institute"
] | [
[
{
"name": "阿伏西地",
"lang": "CN"
},
{
"name": "Alvocidib Hydrochloride",
"lang": "EN"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
{
"name": "ドセタキセル",
"lang": "JP"
}
]
] | null |
NCT01178099 | [
{
"id_field": "org_study_id",
"id_value": [
"13746"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"H7T-MC-TAEJ"
]
}
] | https://clinicaltrials.gov/study/NCT01178099 | An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults | The purpose of this study is to measure the exposure to prasugrel's active metabolite and the pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD). | A Pharmacokinetic and Pharmacodynamic Assessment of Prasugrel in Healthy Adults and Adults With Sickle Cell Disease | [
{
"description": "Oral, daily for 12 days",
"name": "Prasugrel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CS747",
"Effient",
"Efient",
"LY650315"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants<60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).",
"design_group_title": "Prasugrel",
"... | [
"Anemia, Sickle Cell"
] | [
"Eli Lilly & Co."
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "盐酸普拉格雷",
"lang": "CN"
},
{
"name": "Prasugrel Hydrochloride",
"lang": "EN"
},
{
"name": "プラスグレル塩酸塩",
"lang": "JP"
}
]
] | null |
NCT04557397 | [
{
"id_field": "org_study_id",
"id_value": [
"2020-013-00US2"
]
}
] | https://clinicaltrials.gov/study/NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects. | A Phase 1 Open-label 2-Part 2-Period Fixed-sequence Crossover Study To Assess The Effect Of Itraconazole, A Strong CYP3A Inhibitor, And The Effect Of Rifampin, A Strong CYP3A Inducer, On Pharmacokinetics Of Fruquintinib In Healthy Subjects | [
{
"description": "oral VEGFR inhibitor",
"name": "Fruquintinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"HMPL-013"
],
"type": "Drug"
},
{
"description": "a synthetic triazole antifungal agent",
"name": "Itraconazole",
"normalized_type": "... | [
{
"design_group_description": "Subjects will receive fruquintinib, alone and with itraconazole.",
"design_group_title": "Part A",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "a synthetic triazole antifungal agent",
"intervention_name": "Itracon... | [
"Drug Drug Interaction"
] | [
"Hutchison MediPharma Ltd."
] | [
"Labcorp Drug Development, Inc."
] | [
[
{
"name": "伊曲康唑",
"lang": "CN"
},
{
"name": "Itraconazole",
"lang": "EN"
},
{
"name": "イトラコナゾール",
"lang": "JP"
}
],
[
{
"name": "利福平",
"lang": "CN"
},
{
"name": "Rifampin",
"lang": "EN"
},
{
"name": "... | null |
NCT00150215 | [
{
"id_field": "org_study_id",
"id_value": [
"A6241001"
]
}
] | https://clinicaltrials.gov/study/NCT00150215 | A First In Human Study Of PF-00184562 In Healthy Volunteers | The purposes of this study are:<br/>* To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and<br/>* To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine. | An Oral, Rising Single-Dose Tolerance, Pharmacokinetic, and Pharmacodynamic Study of Pf-00184562 Capsules In Healthy Volunteers | [
{
"name": "PF-00184562",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Olanzapine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Schizophrenia"
] | [
"Pfizer Inc."
] | [
"Pharmaceutical Product Development LLC"
] | [
[
{
"name": "PF-184562",
"lang": "EN"
}
],
[
{
"name": "奥氮平",
"lang": "CN"
},
{
"name": "Olanzapine",
"lang": "EN"
},
{
"name": "オランザピン",
"lang": "JP"
}
]
] | null |
NCT04380207 | [
{
"id_field": "org_study_id",
"id_value": [
"Qpex-200"
]
}
] | https://clinicaltrials.gov/study/NCT04380207 | P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV | QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze cephalosporins and can be found in Enterobacteriaceae ... | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX7728 Alone and in Combination With QPX2014 in Healthy Adult Subjects | [
{
"description": "antibiotic",
"name": "QPX7728",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"IV"
],
"type": "Drug"
},
{
"description": "Placebo comparator",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other... | [
{
"design_group_description": "antibiotic",
"design_group_title": "QPX7728",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "antibiotic",
"intervention_name": "QPX77... | [
"Bacterial Infections"
] | [
"Qpex Biopharma, Inc."
] | [
"Biomedical Advanced Research & Development Authority (Barda)"
] | [
[
{
"name": "Xeruborbactam",
"lang": "EN"
}
],
[
{
"name": "QPX-2014",
"lang": "EN"
}
]
] | null |
NCT07217496 | [
{
"id_field": "org_study_id",
"id_value": [
"25525"
]
},
{
"id_domain": "NCI Clinical Trials Reporting Program (CTRP)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2025-07330"
]
},
{
"id_field": "secondary_id",
"id_valu... | https://clinicaltrials.gov/study/NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (... | Phase Ib Trial Combining N-803 and Pembrolizumab With Shorter Duration of Enfortumab Vedotin in Treatment-Naïve Patients With Metastatic Urothelial Carcinoma | [
{
"description": "Given subcutaneously (SC)",
"name": "Nogapendekin Alfa Inbakicept (N803)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"N803",
"Nogapendekin Alfa Inbakicept"
],
"type": "Drug"
},
{
"description": "Given intravenously (IV)",
... | [
{
"design_group_description": "Participants with unresectable locally advanced (LA) or metastatic urothelial carcinoma (mUC) will receive N-803 plus Enfortumab Vedotin (EV) and Pembrolizumab on Day 1 and EV on Day 8 in a repeated 3-week cycle until disease progression or unacceptable toxicity. EV treatment is p... | [
"Metastatic Urothelial Carcinoma",
"Urothelial Carcinoma",
"Locally Advanced Urothelial Carcinoma",
"Urothelial Cancer"
] | [
"The University of California, San Francisco"
] | [
"ImmunityBio, Inc."
] | [
[
{
"name": "诺格白介素α-因奇西普",
"lang": "CN"
},
{
"name": "Nogapendekin alfa inbakicept-pmln",
"lang": "EN"
}
],
[
{
"name": "维恩妥尤单抗",
"lang": "CN"
},
{
"name": "Enfortumab Vedotin-ejfv",
"lang": "EN"
},
{
"name": "エンホルツマブ ベドチン... | null |
NCT00003925 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000067112"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA022453"
]
},
{
"id_field": "secondary_id",
"id_value": [
"WSU-D-1641"
]
},
{
"id_field": ... | https://clinicaltrials.gov/study/NCT00003925 | Combination Chemotherapy In Treating Patients With Advanced Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.<br/>PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine, fluorouracil-uracil and leucovorin in treating patients who have... | Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin | [
{
"name": "gemcitabine hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "leucovorin calcium",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug... | null | [
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"Barbara Ann Karmanos Cancer Institute"
] | [
"National Cancer Institute"
] | [
[
{
"name": "尿嘧啶替加氟",
"lang": "CN"
},
{
"name": "Tegafur/Uracil",
"lang": "EN"
},
{
"name": "テガフール/ウラシル",
"lang": "JP"
}
],
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
... | null |
NCT00532974 | [
{
"id_field": "org_study_id",
"id_value": [
"EP-HIV-1090"
]
},
{
"id_field": "acronym",
"id_value": [
"EP1090"
]
}
] | https://clinicaltrials.gov/study/NCT00532974 | A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) | The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL epitope DNA vaccine (EP1090) in HIV-1 infected individuals receiving potent combination antiretroviral therapy (ART) and who have undetectabl... | A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART) | [
{
"description": "Low dose",
"name": "EP1090",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"description": "High dose",
"name": "EP1090",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_mu... | null | [
"HIV Infections"
] | [
"Epimmune, Inc."
] | [
"Pharmexa A/S",
"Pharmexa-Epimmune, Inc."
] | [
[
{
"name": "HIV-1 CTL epitope-based DNA vaccine(VaxOnco, Inc.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EP1090"
}
] |
NCT07086521 | [
{
"id_field": "org_study_id",
"id_value": [
"RES001-FSHD-01"
]
}
] | https://clinicaltrials.gov/study/NCT07086521 | Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD) | The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell product (ULSC) performs when treating Facioscapulohumeral Muscular Dystrophy (FSHD) 1 or 2. It will assess safety and preliminary efficacy in relieving symptoms of FSHD with ULSC administered in two intravenous (IV) doses o... | A Phase 1, Double-blinded, Randomized, Dose-repeating, Placebo-controlled, Cross-over Study to Assess the Safety and Preliminary Efficacy of Allogeneic ULSC on Disease Severity in Facioscapulohumeral Muscular Dystrophy (FSHD) | [
{
"description": "Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1 x 10^8 ULSC will be added to into 250 sterile saline for infusion (total volume of 260 mL volume).",
"name": "ULSC",
"normal... | [
{
"design_group_description": "Group 1 will receive a dose of 1 x 10^8 ULSC through IV administration on Day 0 and Month 3 (two doses, 2 x 10^8 ULSC in total from both doses). They will then cross-over to Placebo IV administrations on Month 6 and Month 9.",
"design_group_title": "Group 1: ULSC first; Placeb... | [
"FSHD - Facioscapulohumeral Muscular Dystrophy"
] | [
"Restem Group, Inc."
] | [
"Solve Fshd Holdings Ltd."
] | [
[
{
"name": "Restem-L",
"lang": "EN"
}
]
] | null |
NCT04658667 | [
{
"id_field": "org_study_id",
"id_value": [
"S-19-01"
]
},
{
"id_domain": "MHRP",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"RV 546"
]
},
{
"id_domain": "USAMRDC/WRAIR",
"id_field": "secondary_id",
"id_type": "Other Ident... | https://clinicaltrials.gov/study/NCT04658667 | HIV Vaccine in HIV-uninfected Adults | The purpose of this study is to test whether delayed boosting (an extra administration of a vaccine) with the IHV01 (FLSC) protein and A244/AHFG with or without ALFQ will cause the body to make higher amounts of antibodies or different types of antibodies after the vaccination. | Randomized, Double Blind Evaluation of Late Boost Strategies With IHV01 (FLSC in Aluminum Phosphate) and A244 With or Without ALFQ for HIV-uninfected Participants in the HIV Vaccine Trial RV306 / WRAIR 1920 | [
{
"description": "IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid l... | [
{
"design_group_description": "Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg).",
"design_group_title": "Full dose IHV01 and A244",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"int... | [
"HIV"
] | [
"U S Army Medical Research & Development Command"
] | [
"Case Western Reserve University",
"University of Maryland Baltimore",
"Duke University"
] | [
[
{
"name": "A244",
"lang": "EN"
}
],
[
{
"name": "FLSC vaccine(Profectus BioSciences, Inc.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RV546"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "WRAIR 1920"
}
] |
NCT02361112 | [
{
"id_field": "org_study_id",
"id_value": [
"BLTN-Ic"
]
},
{
"id_field": "acronym",
"id_value": [
"BLTN-Ic"
]
}
] | https://clinicaltrials.gov/study/NCT02361112 | Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer | Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer:<br/>To evaluate the safety and tolerability of pyrotinib, and the ... | A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer | [
{
"name": "pyrotinib combined with capecitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "pyrotinib combined with capecitabine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "pyrotinib combined with capecitabine",
"intervention_type": "Dru... | [
"Metastatic Breast Cancer"
] | [
"Jiangsu Hengrui Pharmaceuticals Co., Ltd."
] | [
"Cancer Hospital Chinese Academy of Medical Sciences"
] | [
[
{
"name": "马来酸吡咯替尼",
"lang": "CN"
},
{
"name": "Pyrotinib Maleate",
"lang": "EN"
}
],
[
{
"name": "卡培他滨",
"lang": "CN"
},
{
"name": "Capecitabine",
"lang": "EN"
},
{
"name": "カペシタビン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BLTN-Ic"
}
] |
NCT00004895 | [
{
"id_field": "org_study_id",
"id_value": [
"NU 97X1"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NU-97X1"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-G00-1685"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NU-97X1;N... | https://clinicaltrials.gov/study/NCT00004895 | Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.<br/>PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that... | Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study | [
{
"name": "octreotide acetate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Colorectal Cancer",
"Constipation, Impaction, and Bowel Obstruction",
"Extrahepatic Bile Duct Cancer",
"Gastric Cancer",
"Gastrointestinal Stromal Tumor",
"Nausea and Vomiting",
"Ovarian Cancer",
"Pancreatic Cancer",
"Peritoneal Cavity Cancer",
"Small Intestine Cancer"
] | [
"Northwestern University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "醋酸奥曲肽",
"lang": "CN"
},
{
"name": "Octreotide Acetate",
"lang": "EN"
},
{
"name": "オクトレオチド酢酸塩",
"lang": "JP"
}
]
] | null |
NCT02251912 | [
{
"id_field": "org_study_id",
"id_value": [
"12-1862b"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R21AA021927-01A1"
]
},
{
"id_field": "acronym",
"id_value": [
"OTETOH-3"
]
}
] | https://clinicaltrials.gov/study/NCT02251912 | Oxytocin Treatment of Alcohol Dependence | Purpose: Test whether oxytocin treatment decreases drinking in people who have been consuming alcohol heavily for long periods and are physically and psychologically dependent on alcohol.<br/>Participants: 50 adults with alcohol dependence<br/>Procedures (methods): Oxytocin or placebo will be administered three times a... | Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial | [
{
"description": "10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks",
"name": "Intranasal Oxytocin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Syntocinon spray"
],
"type": "Drug"
},
{
"description": "10 ins... | [
{
"design_group_description": "Intranasal oxytocin doses 2-3 times/day for 12 weeks",
"design_group_title": "Active",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "10 insu... | [
"Alcohol Dependence"
] | [
"The University of North Carolina at Chapel Hill"
] | [
"National Institute on Alcohol Abuse & Alcoholism"
] | [
[
{
"name": "缩宫素",
"lang": "CN"
},
{
"name": "Oxytocin",
"lang": "EN"
},
{
"name": "オキシトシン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "ad24d20e023888eaa89420d9ee2e9a28",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "OTETOH-3"
}
] |
NCT07167966 | [
{
"id_field": "org_study_id",
"id_value": [
"ATRI-014-A"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AG078457"
]
},
{
"id_field": "acronym",
"id_value": [
"ATP"
]
}
] | https://clinicaltrials.gov/study/NCT07167966 | Alzheimer's Tau Platform: Regimen A - AADvac1 | The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.<br/>Regimen A will evaluate the safety and efficacy of AADvac... | Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1 | [
{
"description": "Subcutaneous injection of AADvac1",
"name": "AADvac1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Active comparator: intravenous infusion of donanemab",
"name": "Donanemab",
"normalized_type": "3d1aa88261d64c0384137239... | [
{
"design_group_description": "Intravenous infusions of donanemab for 6 months, followed by subcutaneous injections of AADvac1 over 24 months (n = 150)",
"design_group_title": "AADvac1 monotherapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61... | [
"Preclinical Alzheimer's Disease",
"Prodromal Alzheimer's Disease",
"Alzheimer Disease"
] | [
"University of Southern California"
] | [
"The Massachusetts General Hospital",
"National Institute on Aging",
"The University of California, San Francisco",
"Alzheimer's Disease Research Center",
"AXON Neuroscience SE"
] | [
[
{
"name": "Alzheimer's disease vaccine(Axon Biochemicals BV)",
"lang": "EN"
}
],
[
{
"name": "多奈单抗",
"lang": "CN"
},
{
"name": "Donanemab-AZBT",
"lang": "EN"
},
{
"name": "ドナネマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ATP"
}
] |
NCT04757090 | [
{
"id_field": "org_study_id",
"id_value": [
"202103039"
]
}
] | https://clinicaltrials.gov/study/NCT04757090 | 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111 | This is an open-label, single center, pilot study to assess the feasibility of baseline 89Zr-trastuzumab PET/CT to predict response to treatment with monotherapy MT-5111 | A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111 | [
{
"description": "-To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of \"cold\" unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-nor... | [
{
"design_group_description": "* Enrolled subjects will be asked to undergo 18F-FDG PET/CT imaging (if not performed within the previous 90 days) and 89Zr-trastuzumab PET/CT imaging at baseline prior to the start of monotherapy MT-5111 treatment. Standard of care 18F-FDG PET/CT examinations performed within 90 ... | [
"HER2-positive Solid Tumor",
"HER-2 Positive Cancer"
] | [
"Washington University School of Medicine"
] | [
"Molecular Templates, Inc."
] | [
[
{
"name": "89Zr-trastuzumab",
"lang": "EN"
}
]
] | null |
NCT04576793 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAS7810"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AG063888"
]
},
{
"id_field": "acronym",
"id_value": [
"ADVISe"
]
}
] | https://clinicaltrials.gov/study/NCT04576793 | Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease | The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the i... | Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease | [
{
"description": "11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzhei... | [
{
"design_group_description": "* Mild Cognitive Impairment<br/>* Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties<br/>* Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties<br/>* Amnestic Alzheimer's disease - a \"typic... | [
"Alzheimer Disease"
] | [
"Columbia University"
] | [
"National Institute on Aging"
] | [
[
{
"name": "Florquinitau F18",
"lang": "EN"
}
],
[
{
"name": "氟[¹⁸F]贝他苯",
"lang": "CN"
},
{
"name": "Florbetaben F-18",
"lang": "EN"
}
],
[
{
"name": "[11C]ER-176",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ADVISe"
}
] |
NCT03593447 | [
{
"id_field": "org_study_id",
"id_value": [
"TGDAG-C-2"
]
}
] | https://clinicaltrials.gov/study/NCT03593447 | To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients | A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection. | A Multicenter, Randomized, Open-label, Dose-ranging, Phase II Study to Evaluate the Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in Treatment naïve Subjects With Chronic Hepatic C Virus Genotype I Infection | [
{
"description": "Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg",
"name": "non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Group2: TG-2349 400 mg + DAG181 200 mg + R... | [
{
"design_group_description": "HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin",
"design_group_title": "non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "7... | [
"Chronic Hepatics C Virus (HCV) Genotype 1",
"Non-Cirrhotic",
"Cirrhosis",
"Treatment naïve"
] | [
"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd."
] | [
"Peking University People's Hospital"
] | [
[
{
"name": "磷酸依米他韦",
"lang": "CN"
},
{
"name": "Emitasvir Phosphate",
"lang": "EN"
}
],
[
{
"name": "伏拉瑞韦",
"lang": "CN"
},
{
"name": "Furaprevir",
"lang": "EN"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{... | null |
NCT00004157 | [
{
"id_field": "org_study_id",
"id_value": [
"1365.00"
]
},
{
"id_field": "secondary_id",
"id_value": [
"FHCRC-1365.00"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-G99-1622"
]
},
{
"id_domain": "PDQ",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT00004157 | Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side effects after transplant.<br/>PURPOSE: Phase II trial to study the effectiveness of interleukin-... | Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) | [
{
"name": "filgrastim",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"name": "recombinant interleukin-11",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | null | [
"Breast Cancer",
"Gestational Trophoblastic Tumor",
"Kidney Cancer",
"Lymphoma",
"Neuroblastoma",
"Ovarian Cancer",
"Sarcoma",
"Testicular Germ Cell Tumor"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "非格司亭 （安进）",
"lang": "CN"
},
{
"name": "Filgrastim (Amgen)",
"lang": "EN"
},
{
"name": "フィルグラスチム（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03207334 | [
{
"id_field": "org_study_id",
"id_value": [
"UF-HEM-004"
]
},
{
"id_domain": "Novartis Pharmaceuticals Corporation",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"CPKC412AUS61T"
]
},
{
"id_domain": "Univeristy of Florida",... | https://clinicaltrials.gov/study/NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML. | A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML) | [
{
"description": "Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase<br/>Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for... | [
{
"design_group_description": "Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or comp... | [
"Acute Myeloid Leukemia"
] | [
"University of Florida"
] | [
"Novartis Pharmaceuticals Corp."
] | [
[
{
"name": "米哚妥林",
"lang": "CN"
},
{
"name": "Midostaurin",
"lang": "EN"
},
{
"name": "ミドスタウリン",
"lang": "JP"
}
],
[
{
"name": "阿糖胞苷",
"lang": "CN"
},
{
"name": "Cytarabine",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "UF-HEM-004"
}
] |
NCT00831649 | [
{
"id_field": "org_study_id",
"id_value": [
"ELN100226-RA251"
]
}
] | https://clinicaltrials.gov/study/NCT00831649 | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of natalizumab in subjects with active rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX) | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | [
{
"name": "natalizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"TYSABRI"
],
"type": "Drug"
}
] | [
{
"design_group_title": "natalizumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "natalizumab",
"intervention_other_name": [
"TYSABRI"
],
"interv... | [
"Rheumatoid Arthritis"
] | [
"Biogen, Inc."
] | [
"Elan Corp. Plc"
] | [
[
{
"name": "那他珠单抗",
"lang": "CN"
},
{
"name": "Natalizumab",
"lang": "EN"
},
{
"name": "ナタリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT01843829 | [
{
"id_field": "org_study_id",
"id_value": [
"2012/VCC/0009"
]
},
{
"id_field": "acronym",
"id_value": [
"NeoSCOPE"
]
}
] | https://clinicaltrials.gov/study/NCT01843829 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less than a quarter have resectable disease at diagnosis. There is a general lack of consistency in the standard of care for patients across UK hospitals. Patients are either treated with a) chemotherapy followed by surgical removal ... | A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer | [
{
"name": "Oxaliplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Capecitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",... | [
{
"design_group_description": "2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)<br/>then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions<br/>then surgery.<br/>All drugs will be... | [
"Oesophageal Cancer"
] | [
"Velindre NHS Trust"
] | [
"Cancer Research UK"
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パク... | [
{
"identifier_source": [
{
"code": "02aae45daed9a9954a49522a239ee443",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "222025509deea522a98aeeda405a8355",
"s... |
NCT02270814 | [
{
"id_field": "org_study_id",
"id_value": [
"201410073"
]
},
{
"id_field": "acronym",
"id_value": [
"CACTUX"
]
}
] | https://clinicaltrials.gov/study/NCT02270814 | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma | The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously had proble... | Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) | [
{
"name": "nab-paclitaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abraxane",
"Albumin-bound paclitaxel",
"Paclitaxel protein-bound"
],
"type": "Drug"
},
{
"name": "Cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:<br/>* nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by<br/>* cisplatin given intravenously over 60 minutes on an outpatient basis O... | [
"Head and Neck Cancer",
"Head and Neck Squamous Cell Carcinoma",
"Cancer of the Head and Neck"
] | [
"Washington University School of Medicine"
] | [
"Celgene Corp."
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CACTUX"
}
] |
NCT01816594 | [
{
"id_field": "org_study_id",
"id_value": [
"CBKM120F2203"
]
},
{
"id_field": "acronym",
"id_value": [
"NeoPHOEBE"
]
}
] | https://clinicaltrials.gov/study/NCT01816594 | NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer prior to surgery (neo-adjuvant setting). | NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Can... | [
{
"description": "Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.",
"name": "BKM120",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Buparsilib"
],
"type": "Drug"
},
{
"descripti... | [
{
"design_group_description": "BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.",
"design_group_title": "BKM120 + Trastuzumab + paclitaxel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"inter... | [
"HER2-positive Newly Diagnosed, Primary Breast Cancer"
] | [
"Novartis Pharmaceuticals Corp."
] | [
"Grupo SOLTI",
"Breast International Group",
"GBG Forschungs GmbH"
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "3882a525235e22a22d022242de2a08aa",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "44290524a05240ad4438d93535da22e3",
"s... |
NCT06488105 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00104057"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1K23HL169929-01A1"
]
},
{
"id_field": "acronym",
"id_value": [
"EMERALD RCT"
]
},
{
"id_field": ... | https://clinicaltrials.gov/study/NCT06488105 | Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial | Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being e... | Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial | [
{
"description": "moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)",
"name": "Statin (rosuvastatin 10 or 40 mg daily, depending on risk)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Crestor"
],
"type": "Drug"
... | [
{
"design_group_description": "In the EMERALD arm, care will vary by risk level: (1) patients with known atherosclerotic cardiovascular disease (ASCVD) will qualify for a high-intensity statin (rosuvastatin 40 mg daily) and referral to cardiology for secondary prevention, (2) patients with low-density lipoprote... | [
"Lipid Disorder",
"Hypercholesterolemia",
"Cardiovascular Diseases",
"Atherosclerosis"
] | [
"Wake Forest School of Medicine"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health"
] | [
[
{
"name": "瑞舒伐他汀钙",
"lang": "CN"
},
{
"name": "Rosuvastatin Calcium",
"lang": "EN"
},
{
"name": "ロスバスタチンカルシウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EMERALD RCT"
}
] |
NCT00486291 | [
{
"id_field": "org_study_id",
"id_value": [
"OB-202"
]
}
] | https://clinicaltrials.gov/study/NCT00486291 | Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics | The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults. | A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults | [
{
"description": "phentermine 15mg/topiramate 100mg",
"name": "VI-0521",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "matched placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Phentermine 15mg/topiramate 100mg",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "phentermine 15mg/topiramate 100... | [
"Type 2 Diabetes Mellitus"
] | [
"VIVUS, Inc."
] | [
"Synteract, Inc."
] | [
[
{
"name": "盐酸芬特明/托吡酯",
"lang": "CN"
},
{
"name": "Phentermine Hydrochloride/Topiramate",
"lang": "EN"
}
]
] | null |
NCT04414514 | [
{
"id_field": "org_study_id",
"id_value": [
"001"
]
}
] | https://clinicaltrials.gov/study/NCT04414514 | Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment | Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity.<br/>Investigators aim to:<br/>* Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment.<br/>* Invest... | Exploratory Trial of Ruxolitinib 1.5% Cream for the Treatment of Early Stage Hidradenitis Suppurativa | [
{
"description": "Topical Ruxolitinib 1.5% Cream",
"name": "Ruxolitinib 1.5% Cream",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks",
"design_group_title": "Open-label",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": ... | [
"Hidradenitis Suppurativa"
] | [
"Hershey Medical Center"
] | [
"Incyte Corp."
] | [
[
{
"name": "磷酸芦可替尼",
"lang": "CN"
},
{
"name": "Ruxolitinib Phosphate",
"lang": "EN"
},
{
"name": "ルキソリチニブリン酸塩",
"lang": "JP"
}
]
] | null |
NCT03256045 | [
{
"id_field": "org_study_id",
"id_value": [
"9757"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2017-00453"
]
},
{
"id_domain": "Fred Hutch/University of Washing... | https://clinicaltrials.gov/study/NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemothe... | CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing | [
{
"description": "Given IV",
"name": "Carfilzomib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Kyprolis",
"PR-171"
],
"type": "Drug"
},
{
"description": "Undergo in vitro chemosensitivity testing",
"name": "Chemosensitivity Assay",
"no... | [
{
"design_group_description": "Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients ... | [
"Recurrent Plasma Cell Myeloma",
"Refractory Plasma Cell Myeloma"
] | [
"University of Washington"
] | [
"National Cancer Institute",
"Secura Bio, Inc."
] | [
[
{
"name": "乳酸帕比司他",
"lang": "CN"
},
{
"name": "Panobinostat lactate",
"lang": "EN"
},
{
"name": "パノビノスタット乳酸塩",
"lang": "JP"
}
],
[
{
"name": "卡非佐米",
"lang": "CN"
},
{
"name": "Carfilzomib",
"lang": "EN"
},
... | null |
NCT00083759 | [
{
"id_field": "org_study_id",
"id_value": [
"ELN100226-RA201"
]
}
] | https://clinicaltrials.gov/study/NCT00083759 | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood cells, known as lymp... | A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX) | [
{
"name": "natalizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"TYSABRI"
],
"type": "Drug"
},
{
"name": "placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "natalizumab",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_name": "natalizumab",
"intervention_other_name": [
"TYSABRI"
],
"i... | [
"Rheumatoid Arthritis"
] | [
"Biogen, Inc."
] | [
"Elan Corp. Plc"
] | [
[
{
"name": "那他珠单抗",
"lang": "CN"
},
{
"name": "Natalizumab",
"lang": "EN"
},
{
"name": "ナタリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02594098 | [
{
"id_field": "org_study_id",
"id_value": [
"GCO 15-1486"
]
},
{
"id_domain": "Novartis Pharmaceuticals Corporation",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CAIN457AUS02T"
]
}
] | https://clinicaltrials.gov/study/NCT02594098 | Secukinumab for Treatment of Atopic Dermatitis | Atopic Dermatitis, also known as atopic eczema, or eczema, is a common skin disease that can affect males and females of all ages, but often starts in childhood. Recent studies show at least 4-7% of adults and 15-25% of children to be affected, with one third of patients having severe disease. It results in very itchy,... | A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Moderate to Severe Atopic Dermatitis | [
{
"description": "At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.",
"name": "Secukinumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter... | [
{
"design_group_description": "Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes",
"design_group_title": "Secukinumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interven... | [
"Atopic Dermatitis"
] | [
"Icahn School of Medicine at Mount Sinai"
] | [
"Novartis AG"
] | [
[
{
"name": "司库奇尤单抗",
"lang": "CN"
},
{
"name": "Secukinumab",
"lang": "EN"
},
{
"name": "セクキヌマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03075527 | [
{
"id_field": "org_study_id",
"id_value": [
"16-549"
]
}
] | https://clinicaltrials.gov/study/NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma.<br/>The drugs involved in this study are:<br/>* Durvalumab<br/>* Tremelimumab | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | [
{
"description": "Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.",
"name": "Tremelimumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CP-675,206"
],
"type": "Drug"
},
{
"description": "Durvalumab is a drug tha... | [
{
"design_group_description": "Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, u... | [
"Mesothelioma"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "曲麦利尤单抗",
"lang": "CN"
},
{
"name": "Tremelimumab",
"lang": "EN"
},
{
"name": "トレメリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "度伐利尤单抗",
"lang": "CN"
},
{
"name": "Durvalumab",
"lang": "EN"
},
{
... | null |
NCT03588754 | [
{
"id_field": "org_study_id",
"id_value": [
"2000022090"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AA022285"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1U54... | https://clinicaltrials.gov/study/NCT03588754 | Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking? | For this protocol, the investigators plan to conduct a pilot study evaluating the effect of propranolol on alcohol consumption. Using a parallel design, the investigators plan to randomize 20 non-treatment seeking adults with alcohol use disorders (DSM-5) to propranolol extended release (160mg/day or placebo; n=10 per ... | Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking? | [
{
"description": "Propranolol Extended Release (160mg/day).",
"name": "Propranolol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo pill administered orally.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b"... | [
{
"design_group_description": "Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.",
"design_group_title": "Propranolol",
"design_group_type": "Experimental",
"... | [
"Alcohol Drinking"
] | [
"Yale University"
] | [
"National Institute on Alcohol Abuse & Alcoholism"
] | [
[
{
"name": "盐酸普萘洛尔",
"lang": "CN"
},
{
"name": "Propranolol Hydrochloride",
"lang": "EN"
},
{
"name": "プロプラノロール塩酸塩",
"lang": "JP"
}
]
] | null |
NCT03768375 | [
{
"id_field": "org_study_id",
"id_value": [
"DLY201812"
]
}
] | https://clinicaltrials.gov/study/NCT03768375 | Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma. | A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | [
{
"description": "Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib",
"name": "conventional chemotherapy(FORFIRINOX) combined with target agents",
"normalized_type": "... | [
{
"design_group_description": "The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.",
"design_group_title": "target therap",
"design_group_type": "Experimental",
"design_group_type_norma... | [
"Cholangiocarcinoma of the Extrahepatic Bile Duct",
"Gallbladder Cancer"
] | [
"Shanghai Jiao Tong University"
] | [
"Ruijin Hospital",
"Xinhua Hospital",
"Shanghai Renji Hospital Management Co., Ltd.",
"Shanghai Eastern Hepatobiliary Surgery Hospital",
"Shanghai Huashan Hospital"
] | [
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
"name": "ホリナートカルシウム",
"lang": "JP"
}
],
[
{
"name": "聚乙二醇伊立替康",
"lang": "CN"
},
{
"name": "PEG-Irinotecan",
"lang": "EN"
}
]... | null |
NCT04432389 | [
{
"id_field": "org_study_id",
"id_value": [
"000013/BT"
]
},
{
"id_field": "acronym",
"id_value": [
"ALLOB-TF2"
]
}
] | https://clinicaltrials.gov/study/NCT04432389 | Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture | Although the majority of tibial fractures heal normally, some fractures may not heal within the usual time frame and is known as delayed bone healing within 4 to 6 months and absence of bone healing within 9 to 12 months in the most severe case of. Several factors can increase the risks of delayed healing complications... | Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture | [
{
"description": "After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.",
"name": "ALLOB",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Placebo injected is a saline solution injectable grade (4 mL of 0.9... | [
{
"design_group_description": "Single injection of ALLOB at fracture site (4 ml)",
"design_group_title": "ALLOB",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "After thawi... | [
"Tibial Fracture"
] | [
"Bone Therapeutics SA"
] | [
"ICON plc"
] | [
[
{
"name": "Allogeneic osteoblastic cell therapy (Bone Therapeutics)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ALLOB-TF2"
}
] |
NCT00024271 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068907"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CPMC-IRB-13799"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-G01-2015"
]
}
] | https://clinicaltrials.gov/study/NCT00024271 | Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs directly into the tumor after surgery and combining them with radiation therapy may kill more tumor cells.<br/>PURPOSE: Phase II trial to study the effectiveness of combining surgery,... | Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma | [
{
"name": "recombinant interferon gamma",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "doxorubicin hy... | null | [
"Malignant Mesothelioma"
] | [
"The Herbert Irving Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "丝裂霉素",
"lang": "CN"
},
{
"name": "Mitomycin",
"lang": "EN"
},
{
"name": "マイトマイシンC",
"lang": "JP"
}
],
[
{
"name": "盐酸多柔比星",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride",
"lang": "EN"
},
... | null |
NCT02643654 | [
{
"id_field": "org_study_id",
"id_value": [
"HIDRA04"
]
}
] | https://clinicaltrials.gov/study/NCT02643654 | MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB | Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. Although adalimumab is recently licensed for moderate to severe HS, many cases fail to respond or relapse during treatment. Favorable outcomes from a recently conducted double-blind randomized clinical study on the efficacy of anakinra, one interleu... | A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy | [
{
"description": "This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal",
"name": "MABp1",
"normalized_type": "3d1a... | [
{
"design_group_description": "The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formu... | [
"Hidradenitis Suppurativa"
] | [
"National & Kapodistrian University of Athens"
] | [
"Hellenic Institute for the Study of Sepsis"
] | [
[
{
"name": "贝迈奇单抗(XBiotec)",
"lang": "CN"
},
{
"name": "Bermekimab",
"lang": "EN"
}
]
] | null |
NCT01668173 | [
{
"id_field": "org_study_id",
"id_value": [
"12-076"
]
}
] | https://clinicaltrials.gov/study/NCT01668173 | HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET | The purpose of this study is to test a new drug called AUY922. AUY922 is not FDA-approved. AUY922 is a new kind of drug that attacks a protein called HSP90. HSP90 is found in both normal and cancer cells, but the investigators think it is more important in cancer cells.<br/>This study will see if AUY922 helps people wi... | A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET | [
{
"description": "AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used fo... | [
{
"design_group_description": "This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.",
"design_group_title": "AUY922",
"design_group_type": "Exp... | [
"Myeloproliferative Neoplasms"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Novartis AG"
] | [
[
{
"name": "Luminespib",
"lang": "EN"
}
]
] | null |
NCT02689869 | [
{
"id_field": "org_study_id",
"id_value": [
"2014-005164-15"
]
},
{
"id_field": "acronym",
"id_value": [
"Alternative"
]
}
] | https://clinicaltrials.gov/study/NCT02689869 | Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | Primary Objectives The primary objective of this study is to evaluate the efficacy of the chemotherapy-free combination of ibrutinib and obinutuzumab (GA 101) in patients with previously untreated follicular lymphoma (FL) and a high tumor burden. Primary endpoint to be observed for this is the rate of progression free ... | A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden | [
{
"description": "Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.",
... | [
{
"design_group_description": "Initial therapy 6 cycles of Ibrutinib:<br/>Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.<br/>1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).<br/>Maintenance with another 24 months of ibruti... | [
"Indolent Non-Hodgkin Lymphoma"
] | [
"Ludwig-Maximilians-Universität München"
] | [
"Janssen-Cilag GmbH",
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "伊布替尼",
"lang": "CN"
},
{
"name": "Ibrutinib",
"lang": "EN"
},
{
"name": "イブルチニブ",
"lang": "JP"
}
],
[
{
"name": "奥妥珠单抗",
"lang": "CN"
},
{
"name": "Obinutuzumab",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Alternative"
}
] |
NCT02807805 | [
{
"id_field": "org_study_id",
"id_value": [
"871875"
]
},
{
"id_domain": "UC Davis IRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"UCDCC#260"
]
},
{
"id_domain": "University of California Davis Comprehensive Cancer Center",
... | https://clinicaltrials.gov/study/NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of and... | A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC) | [
{
"description": "Given PO",
"name": "Abiraterone Acetate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CB7630",
"Zytiga"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "Niclosamide",
"normalized_type": "3d1aa88261d64c0384137... | [
{
"design_group_description": "Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (abiraterone acetate, niclosamide, prednisone)",
"design... | [
"Metastatic Prostate Carcinoma",
"Recurrent Prostate Carcinoma",
"Stage IV Prostate Cancer"
] | [
"University of California, Davis"
] | [
"National Cancer Institute"
] | [
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
],
[
{
"name": "醋酸阿比特龙",
"lang": "CN"
},
{
"name": "Abiraterone acetate",
"lang": "EN"
},
{
"name": "アビラテロン酢酸エステル",
"lang": "JP"
}
],
... | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.